Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 eRapa in familial adenomatous polyposis
NL-OMON60866Phase 3Recruiting
- Sponsor
- Biodexa Pharmaceuticals
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sirolimus in Colonic Adenomatous Polyposis (2 arms), sponsored by Biodexa Pharmaceuticals. Primary endpoint: Progression-free survival. Started Dec 2025; status: recruiting.
02
Drugs
sirolimus
03
Conditions
Colonic Adenomatous Polyposis
Beyond the preview
Go deeper on NL-OMON60866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60866.